Respiratory disease pharmacogenetics has been one of the more widely studied
diseaseareas, although almost all studies to date have been in asthma or examined …

Respiratory disease refers to the broad category of illnesses affecting the upper and lower
airways, the lung parenchyma, and the pulmonary vasculature. To date, however, studies …

Pharmacogenetic approaches provide the opportunity to improve prescribing for asthmatic
patients in order to optimise efficacy and prevent side-effects. Currently, there are …

There has been a huge influx of data on the genetics and genomics of respiratory diseases
in the last few years. Powered by large sample sizes from collaborations worldwide, recent …

There is increasing evidence associating differences in drug response to genetic variants.
Pharmacogenetics is the rapidly evolving discipline that identifies these genetic variants to …

Chronic obstructive pulmonary disease (COPD) is a complex genetic disease that develops
as a result of the interaction of multiple susceptibility genes and environmental factors. Major …

Asthma affects an estimated 300 million individuals worldwide, resulting in substantial
morbidity, mortality, and health care utilization. The response to the three major classes of …

Asthma is recognised to arise from complex interactions between environmental exposure
and disease-susceptibility genetic contributions. 1 Pharmacological management of the …

BACKGROUND: For more than a generation, managed care has attempted to eliminate
variation in care delivery in the hope of producing predictable outcomes. But the population …

Although there has been much progress, many findings have not been replicated and
currently known genetic loci only account for a fraction of variability in drug response. More …